“Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field,” stated
“Throughout my career, I have had the pleasure of participating in the launch and commercialization of revolutionary technologies that represent a significant technological leap forward in their field,” stated Mr. Shtengel. “The Nanox.ARC, the company’s novel digital x-ray source technology, is consistent with that theme. With the recent FDA clearance of the Nanox Cart X-Ray System and potential clearance of the multi-source system for commercial use, I am delighted and privileged to join the company and contribute to a successful launch plan that maximizes the reach of this potentially life-saving technology. I look forward to achieve the company’s goal of democratizing medical imaging globally.”
Prior to Tuttnauer, Mr. Shtengel served as
Mr. Shtengel earned his BA in Economics in Business Administration from
Nanox, founded by the serial entrepreneur
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; and Nanox's ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.
ReBlonde for Nanox
Source: Nano-X Imaging